PD-L1
Sign in to saveAlso known as B7 homolog 1, B7-H1 Antigen, PDCD1 ligand 1, B7-H1, programmed cell death 1 ligand 1, CD274, CD274 antigen
Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene.
Protein · UniProt
Programmed cell death 1 ligand 1
- Gene
- CD274
- Organism
- Homo sapiens (Human)
- Length
- 290 aa
- Molecular mass
- 33,275 Da
- Evidence
- 1: Evidence at protein level
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via…
Swiss-Prot (reviewed) · via UniProt
Research
1,895 papers- Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity.Autophagy · 2025
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.Cancer cell · 2019
- A conserved dendritic-cell regulatory program limits antitumour immunity.Nature · 2020
- Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis.Cancer research · 2011
- Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.Nature reviews. Clinical oncology · 2022
via PubMed
Clinical Trials
6 registered- PHASE1/PHASE2TERMINATEDA Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsIncyte Corporation · NCT05949632
- PHASE2ACTIVE_NOT_RECRUITINGStudy Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentAmgen · NCT06502977
- PHASE2RECRUITINGNal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer PatientsThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · NCT06662006
- PHASE1COMPLETEDEvaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCentre Leon Berard · NCT02777710
- PHASE1RECRUITINGPomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVNational Cancer Institute (NCI) · NCT04902443
- PHASE2ACTIVE_NOT_RECRUITINGA Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas CancerLei Zheng · NCT05604560
Wikidata facts
- Instance of
- B7 antigens
Show 3 more facts
- found in taxon
- Homo sapiens
- molecular function
- protein binding
- physically interacts with
- durvalumab
via Wikidata · CC0